Long-term clinical study demonstrates disease modifying effects of anavex®2-73 (blarcamesine) for rett syndrome

New york, june 28, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that long-term clinical study results from the u.s. anavex®2-73-rs-001 (nct03758924) study demonstrate disease modifying effect of anavex®2-73 (blarcamesine) for adult patients with rett syndrome.
AVXL Ratings Summary
AVXL Quant Ranking